Little Rock

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Fibromyalgia2 trials
• Depression1 trial
• Insomnia1 trial

Phase

• Phase 38 trials

Status

• Recruiting5 trials
• Enrolling by invitation2 trials
• Completed1 trial

Lead sponsor

• Axsome Therapeutics, Inc.8 trials

Running trials

• Recruiting

  Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)

  NCT07766655· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Enrolling by invitation

  An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD

  NCT07773883· Phase 3· Axsome Therapeutics, Inc.· Source

• Recruiting

  Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

  NCT07717879· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

  NCT07717892· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Enrolling by invitation

  Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia

  NCT07637162· Phase 3· Axsome Therapeutics, Inc.· Source

• Recruiting

  Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

  NCT07398417· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

• Recruiting

  Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

  NCT06568367· Phase 3· Axsome Therapeutics, Inc.· Source

  Contact: Study Director

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fibromyalgia2 recruiting
• Insomnia1 recruiting

Closed trials

• Completed

  Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol

  NCT06360419· Phase 3· Axsome Therapeutics, Inc.· Source